When sourcing growth hormone-releasing hormone (GHRH) analogs for specialized laboratory applications, understanding the parameters that govern peptide valuation is essential for ensuring experimental integrity. This reference guide provides an analytical breakdown of CJC-1295 DAC pricing dynamics, quality verification metrics, and structural properties established in preclinical research.
When sourcing growth hormone-releasing hormone (GHRH) analogs for specialized laboratory applications, understanding the parameters that govern peptide valuation is essential for ensuring experimental integrity. This reference guide provides an analytical breakdown of CJC-1295 DAC pricing dynamics, quality verification metrics, and structural properties established in preclinical research.
When evaluating CJC-1295 DAC pricing (prijzen), institutional buyers and researchers assess cost per milligram alongside analytical verification standards rather than base retail sticker price. High-purity CJC-1295 DAC pricing is governed by RP-HPLC purity (>99%), mass spectrometry verification, endotoxin quantification (<0.01 EU/mg), and US-based GMP manufacturing compliance for reproducible experimental data.
The economic evaluation of research peptides requires looking beyond nominal purchase prices. Low-cost reagents frequently exhibit unverified purity, significant batch-to-batch variance, or residual TFA (trifluoroacetic acid) levels that compromise cellular assays and animal models. Investing in fully characterized compounds with accessible lot-specific documentation ensures data integrity and eliminates costly experimental failures. Laboratory teams can review our full spectrum of analytical-grade offerings across our all-peptides library.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 29-amino-acid peptide analog of growth hormone-releasing hormone (GHRH). The inclusion of the DAC moiety—a reactive maleimide derivative attached via a linker to the C-terminal lysine residue—fundamentally alters the pharmacokinetic profile of the native peptide sequence.
In biological environments, the maleimide group covalently binds to circulating serum albumin upon administration or incubation. Albumin acts as a carrier macromolecule, protecting the peptide backbone from rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) and renal filtration. Preclinical studies suggest that this bioconjugation extends the half-life of CJC-1295 DAC to several days, compared to the minutes-long half-life observed with unmodified GHRH or CJC-1295 No DAC.
In animal models and in vitro tissue preparations, CJC-1295 DAC has been studied extensively as a long-acting GHRH secretagogue. By binding selectively to the GHRH receptor on pituitary somatotrophs, the compound stimulates signal transduction cascades involving adenylate cyclase and cyclic AMP (cAMP) accumulation.
Research literature demonstrates that sustained activation of the GHRH receptor promotes pulsatiled yet elevated secretion of endogenous growth hormone (GH). Consequently, downstream production of insulin-like growth factor 1 (IGF-1) in hepatic tissue is elevated for extended periods. Investigators utilize CJC-1295 DAC to examine long-term GH/IGF-1 axis modulation, metabolic pathway regulation, cellular proliferation assays, and soft tissue repair research without requiring frequent administration protocols.
To properly position CJC-1295 DAC within an experimental design, researchers frequently compare its pharmacokinetic profile to alternative pituitary secretagogues. While CJC-1295 DAC provides extended bio-availability via serum albumin binding, CJC-1295 No DAC (modified GRF 1-29) offers a short half-life ideal for acute, episodic GH elevation studies. Similarly, Sermorelin represents a truncated 29-amino-acid GHRH segment that closely mimics endogenous GHRH dynamics.
When synergistic GH release mechanisms are required, preclinical research often pairs GHRH analogs with ghrelin receptor agonists. For example, combining a GHRH peptide with Ipamorelin demonstrates dual-receptor activation (GHRHR and GHSR), yielding amplified GH secretion in rodent assays. Additionally, researchers investigating systemic tissue regeneration frequently evaluate these secretagogues alongside cytoprotective compounds like BPC-157. Exploring these distinct profiles allows laboratories to optimize budget allocation based on target half-life and receptor specificity.
A critical factor in evaluating research peptide pricing is the rigorous analytical testing performed before distribution. PX1 Research mandates third-party laboratory verification for every production lot using state-of-the-art analytical instrumentation.
Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) measures chemical purity by isolating the target CJC-1295 DAC sequence from truncated peptide fragments or synthesis side-products. Concurrently, Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular mass and sequence identity. Crucially, research peptides used in delicate cell cultures or animal models must undergo chromogenic LAL testing to verify low endotoxin content (<0.01 EU/mg). High pricing variance across suppliers often reflects the inclusion or omission of these exhaustive quality verification standards. Detailed assay methodologies can be reviewed in our comprehensive research hub.
PX1 Research operates strictly within USA-based, GMP-compliant facilities adhering to ISO 17025 laboratory accreditations. Synthetic peptide manufacturing involves precise step-by-step solid-phase peptide synthesis (SPPS), followed by purification and lyophilization under sterile conditions.
Every vial of CJC-1295 DAC distributed is paired with a lot-specific Certificate of Analysis (COA). Researchers can instantly access COAs containing raw chromatograms, mass spectra, and endotoxin assay reports. This level of traceability guarantees that laboratory budgets are spent on verified, high-purity research materials manufactured under stringent environmental controls.
To preserve structural integrity and prevent degradation, CJC-1295 DAC requires proper storage and reconstitution procedures. Lyophilized peptide powder should be stored in a controlled freezer environment at -20°C or -80°C upon arrival, shielded from light exposure.
For laboratory reconstitution, researchers should utilize sterile bacteriostatic water or laboratory-grade acetic acid solutions depending on solubility parameters and downstream assay requirements. Reconstitution should be performed by gently introducing the solvent along the inner glass wall of the vial, allowing the cake to dissolve naturally without violent vortexing. Reconstituted solutions should be aliquoted to avoid repeated freeze-thaw cycles and maintained at 2°C to 8°C for short-term experimental series.
For university departments, biotechnology organizations, and high-throughput screening laboratories requiring large quantities of CJC-1295 DAC, direct bulk procurement provides substantial cost advantages. Procurement teams can manage supply chains efficiently while locking in volume pricing structures.
PX1 Research offers tailored solutions for institutional clients, featuring dedicated account management, custom synthesis batch sizes, and priority dispatch from our California and Arizona fulfillment hubs. Institutional researchers interested in establishing high-volume laboratory accounts are encouraged to explore our wholesale portal.
What factors determine CJC-1295 DAC research pricing?
Pricing is primarily determined by raw amino acid purity, solid-phase synthesis scale, bioconjugation complexity of the DAC moiety, and the extent of third-party testing (RP-HPLC purity verification, ESI-MS mass verification, and endotoxin assays).
What is the primary structural difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC includes a Drug Affinity Complex (maleimide linker) attached to a C-terminal lysine, enabling covalent binding to circulating serum albumin. CJC-1295 No DAC lacks this moiety, resulting in a significantly shorter biological half-life in preclinical models.
How does CJC-1295 DAC function in preclinical research?
CJC-1295 DAC acts as a long-acting GHRH receptor agonist. In vitro and animal studies show it stimulates pulsatiled secretion of growth hormone (GH) and subsequently elevates downstream hepatic IGF-1 levels for tissue repair and metabolic research.
What analytical documents are provided with PX1 Research peptides?
Every lot of CJC-1295 DAC includes a lot-specific Certificate of Analysis (COA) detailing RP-HPLC purity (>99%), mass spectrometry mass verification, and endotoxin test results from an ISO 17025 accredited laboratory.
How should lyophilized CJC-1295 DAC be stored upon receipt?
Lyophilized CJC-1295 DAC should be stored at -20°C or lower in a dry, dark environment. Once reconstituted for laboratory use, liquid aliquots should be stored at 2°C to 8°C and used within an established experimental timeline.
Where are PX1 Research compounds manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and shipped directly from our primary distribution centers in California and Arizona.
Is CJC-1295 DAC suitable for human clinical consumption?
No. CJC-1295 DAC is strictly manufactured and sold as a research compound for in vitro laboratory assays and animal research applications. It is not for human or veterinary use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.